Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd. Stock Analysis 688076.SS

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. engages in the research and development, and manufactures of peptide drugs and small molecule drugs. The company is headquartered in Lianyungang, Jiangsu and currently employs 2,360 full-time employees. The company went IPO on 2021-05-20. The firm's main business includes customized product business and independently selected product business. Its customized product business includes CDMO (Contract Development and Manufacturing Organization) business, technical service CRO (Contract Research Organization) and transfer business. Its independently selected product business focuses on small molecule chemical drugs and conducts drug research and development in the key treatment areas of diabetes, cardiovascular diseases, tumors and other diseases. The firm mainly operates its businesses in the domestic market and overseas markets.